Nonadjuvanted Bivalent Respiratory Syncytial Virus Vaccination and Perinatal Outcomes

Abstract

In this cohort study of pregnant individuals who delivered at 32 weeks' gestation or later, the RSVpreF vaccine was not associated with an increased risk of PTB and perinatal outcomes. These data support the safety of prenatal RSVpreF vaccination, but further investigation into the risk of HDP is warranted.